Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
Launched by UNIVERSITY OF AARHUS · May 7, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of treatment on swallowing difficulties and overall quality of life in patients with oral cavity cancer (OCC). After treatment, many patients struggle with dysphagia, which means they have trouble swallowing. This can lead to serious issues like weight loss, infections, and a lower quality of life. The goal of this study is to better understand how swallowing ability affects daily life and to find ways to improve rehabilitation for patients after their treatment.
To participate in the study, patients must have a confirmed diagnosis of squamous cell carcinoma in the oral cavity and be receiving treatment aimed at curing their cancer, such as surgery or chemotherapy. The trial will include 100 patients over two years and will track their health, treatment details, and swallowing function before and after treatment. Participants will complete questionnaires and undergo a specific swallowing test at various points during the study. This research aims to provide valuable insights that could help enhance the recovery and well-being of future patients facing similar challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed squamous cell carcinoma with any location in the oral cavity including recurrences. Patients will only be included once
- • Treatment with curative intent (surgery and/or (chemo)radio therapy)
- Exclusion Criteria:
- • Allergy to barium contrast
- • Pregnancy or breastfeeding
- • Inability or unwillingness to complete questionnaires and undergo examinations
About University Of Aarhus
The University of Aarhus, a prestigious research institution located in Denmark, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university fosters an environment that encourages cutting-edge research and the development of novel therapeutic interventions. Committed to ethical standards and patient safety, the University of Aarhus aims to contribute to the global body of medical knowledge while enhancing healthcare outcomes through rigorous scientific inquiry and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aarhus, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported